abdul wafy

cardiology fellow - interest in interventional cardiology and structural heart disease, husband to M ❤️ and father to S 🧡

[abdul wafy @wafy8a]

We are covengers!

[abdul wafy @wafy8a]

@0xProbabillity Halohud

[abdul wafy @wafy8a]

@0xProbabillity GlassDash

[abdul wafy @wafy8a]

@0xProbabillity TestFlight

[abdul wafy @wafy8a]

@jack_9947 Ads

[Zille Huma @Zill_cardio]

#SACIS2026 kicks off tomorrow w/ a high-yield #FellowsWorkshop bringing it all together:

🔹 Cath Lab fundamentals
🔹 IC physiology & imaging
🔹 Contemporary PCI strategies
🔹 #USGuided vasc. closure
🔹 Rx of PCI complication

Practical learning. Expert insights. Don’t miss it!

[Ahmed Mohsen @drahmedmohsen85]

🫀🩸 2026 ESC HF — Iron Deficiency: 10 Take-Home Messages!

Iron deficiency matters even without anaemia!
🧪 TSAT <20% is key
💉 IV iron can improve symptoms, functional capacity & quality of life
🏥 May reduce HF hospitalizations
⚠️ Mortality benefit remains inconclusive

[Zille Huma @Zill_cardio]

#SEOULVALVES2026 successfully delivered 2️⃣ incredible days of live cases, cutting-edge science, expert insights, and inspiring global collaboration.

A huge thank you to the faculty, operators, participants, organizers, and everyone who made this edition truly memorable.🫀✨️

[abdul wafy @wafy8a]

@CathElectroSurg I cant dm you.

[summitmd_cvrf @summitmd_cvrf]

💐We extend our heartfelt appreciation to all participants whose dedication made the 15th #SEOULVALVES2026
an exceptional forum for advancing valvular and structural heart interventions. We look forward to seeing you again in Seoul on August 5-6, 2027!
🔗https://t.co/Qh7cQVdhVv

[Reviews in Cardiovascular Medicine @RCMjournal]

🫀Percutaneous coronary intervention (PCI) after 1 year: what next?

1️⃣Balance ischemic & bleeding risks
2️⃣P2Y12 monotherapy may outperform aspirin
3️⃣High-risk patients need tailored strategies
💡One timeline ≠ all patients.
📄https://t.co/A1d30HW6hi
#Cardiology #PCI

[Bernardita González, MD @Bernilina]

🫀 Management of HFpEF:
2026 ACC Expert Consensus
Decision Pathway @JACCJournals

Full article: https://t.co/gRUaRFCRVQ

Key takeaways here 👇🏼

#Cardiology #HeartFailure

[Dr. Gilbert Tang @GilbertTangMD]

JUST OUT @JCardFail Journal of Cardiac Failure! Our review on the latest evidence on pharmacotherapy in #aorticstenosis and #TAVR. Congrats @sunnygoelmd , #TakayukiOnishiMD, et al for leading this tremendous effort!

Download for FREE here:
https://t.co/kh9zpDSt64

@DoctorKini @georgedangas @AmithoodaMD @KHERA_MD @NoahMossMD @Jcontreras75 @DLBHATTMD @DrDavidReich
@MountSinaiHeart
@MountSinaiNYC
@IcahnMountSinai

[Oliverio @LuisOliverio]

Una grandísima revisión de "Manejo de falla cardíaca descompensada" en JACC 2026. Puntos importantes actualizados:

🟠 Se añaden umbrales confirmatorios de falla: BNP >400 ng/L o NT-proBNP ajustado por edad (>450 ng/L en <50 años; >900 ng/L en 50-75 años)
🟠 Dosis inicial de furosemida — antes: 1-2.5 veces la dosis oral previa. Ahora: 40 mg IV en pacientes sin diurético, y si ya usaba: ≥80 mg IV o dos veces la dosis oral.
🟠 Ahora se sugiere valorar a las 2 horas buscando: uresis ≥300 mL o Na urinario ≥70–80 mmol/L.
🟠 Si hay resistencia ahora se sugiere duplicar el bolo hasta 250 mg de furosemida, considerar acetazolamida o tiazida.
🟠 Ahora se sugiere secuenciación temprana para usar iSGLT-2, ARM (como Espironolactona), ARNI, betabloqueador antes del alta.

Completo en el canal (https://t.co/3O93s10lns).

[Ahmed Ata @Ahmedata7777]

GuideLiner Catheter: The Ultimate Backup Support in Complex PCI

When a balloon or stent simply won't cross the lesion despite optimal wiring, the GuideLiner catheter can be a true game changer.

🔹 What is it?

Thread 👇

[CardiovascularCorner @TrackYourHeart]

Echocardiographic assessment of the right atrium.
Image courtesy of: BE bulwer, MD

[CardiovascularCorner @TrackYourHeart]

Understanding Diastolic Dysfunction with Doppler Echocardiography
This chart beautifully compares Doppler findings in normal vs. varying grades of LV diastolic dysfunction from inflow (E/A, DT) to tissue Doppler (E′/A′), pulmonary vein flow, LA volume, and TR velocity.

Source: Catherine M. Otto, Textbook of Clinical Echocardiography

[CardiovascularCorner @TrackYourHeart]

Echocardiographic evaluation of LV diastolic function made simple by ASE😍

[Hide Yaku, MD, PhD, FHFSA @JP_HFpEF]

🫀【拡張機能評価、もう迷わない】 2025年ASEガイドを臨床目線で整理した総説(EHJCI 2026)📄 "指標が多すぎて結局どう読む？"を解決する段階的アプローチを解説🧵

🔑大原則 ：拡張機能障害＝左室が"充満圧を上げずに"血液を受け入れられない状態。 弛緩障害・スティフネス↑・充満圧↑が3本柱💡 単一指標では捉えきれない「潜在的状態」が今の主流。
🎯起点はe'(僧帽弁輪部速度) 2025年版は心筋障害を重視。 弛緩マーカーe'を最初に評価→もう1指標を足して診断✨ e'が不確実なら他2指標で代替できる柔軟設計。
📶充満圧推定は3段階で：①e'・E/e'・TR速度(orPASP) ②LARS(18%)・肺静脈血流・LAVI・IVRT ③Valsalva等の補助指標 原則"2つ以上の一致"で判断⚠️
🆚2016年版からの進化 4変数分類→e'起点の段階評価へ。 「判定不能」が激減し病態生理と合致✅ AF・肺高血圧・MAC・心移植には専用アルゴリズムも追加🔧
🤖未来はAIへ EMPEROR-Preserved等の大規模試験でも拡張障害は患者選択・予後の鍵。 AIが多次元データから"潜在フェノタイプ"を抽出し早期発見を後押し📈 臨床と画像が食い違えば右心カテも🫀
🔗https://t.co/Lr1stSUC9K

[Jorge Faerron @cardiopedhnn]

Exercise and exercise stress testing in #Brudada_syndrome

https://t.co/VVguPieY7b

[MIЯVΛƬ #IC ༄ ｡° @mirvatalasnag]

Following recent trials, it’s impt to evaluate the totality of evidence &amp; the technical implications to IC

🔗https://t.co/3gJzo8kQk8

@twj1974 @NievesGonzalo1 @nicolasamabile @DrPeterOKane @RaberLorenz @ziadalinyc @sbrugaletta @valeriaparadies @GoranEBC @YChatzizisis @BURZOTTA_F